Role of Combined Anti-PD-1 and Anti-CTLA-4 Therapy in Melanoma Immune Response Background Immune checkpoint inhibitors have made significant progress in clinical oncology, especially anti-PD-1 (anti-programmed death protein 1) and anti-CTLA-4 (anti-cytotoxic T-lymphocyte-associated antigen 4) therapies, which have been proven to induce long-term re...
Background Glioblastoma (GBM) is a highly aggressive central nervous system malignancy with very poor prognosis, typically associated with short patient survival. Although significant advancements have been made in tumor treatment technologies and strategies in recent years, traditional radiotherapy and chemotherapy still struggle to achieve satisf...
Macroscopic and Microscopic Mechanisms of Nicotinamide Metabolism Antagonism: Manipulation of the Gastric Cancer Microenvironment Background Introduction Gastric cancer (GC) is a type of cancer characterized by a unique and heterogeneous tumor microenvironment (TME). Despite advances in immune checkpoint blockade (ICB) therapy for gastric cancer, n...
Diabetic Retinopathy as a Ceramide Disease Reversible by Anti-Ceramide Immunotherapy Background Diabetic Retinopathy (DR) is one of the most common metabolic disorders worldwide. Diabetes not only leads to chronic complications in macrovascular and microvascular systems but also imposes significant socio-economic burdens. As a microvascular complic...
The Therapeutic Role of IFN-γ in Experimental Autoimmune Encephalomyelitis is Mediated by Tolerogenic Subsets of Splenic CD11b+ Myeloid Cells Research Background Multiple sclerosis (MS) is a chronic autoimmune disease characterized by demyelination and axonal damage in the central nervous system (CNS). Although the etiology of MS is unclear, both g...
In the tumor microenvironment (Tumor Microenvironment, TME), Immune Checkpoint Inhibitors (ICIs) targeting PD-1 or PD-L1 enhance the body’s natural ability to eliminate cancer cells by disrupting the inhibitory receptor-ligand interaction. However, even so, critical trials indicate that the response rate for monotherapy is <50%, with a median Progr...
In esophageal squamous cell carcinoma (ESCC), immune checkpoint blockade (ICB) therapy has achieved significant clinical benefits. However, the overall response rate to ICB treatment remains low. This study aims to identify biomarkers for ESCC response to ICB therapy and explore their potential clinical relevance. The authors of the paper come from...
Research Report: Dominance and Persistence of T-Cell Clones in Tumor-Infiltrating Lymphocytes during Expansion in Breast Cancer Background Tumor-infiltrating lymphocytes (TILs) are lymphocytes that naturally infiltrate the tumor microenvironment and exhibit reactivity to the tumor. This subject is one of the most actively researched areas in tumor ...
Generation of Clinically Applicable CAR-NKT Cells Research Background Chimeric Antigen Receptor (CAR) T cell therapy has been approved by the Food and Drug Administration (FDA) for the treatment of B-cell malignancies and multiple myeloma. However, the use of autologous CAR-T cell products presents challenges such as high costs, long manufacturing ...
AAV-SB-CRISPR Screening Identifies Genetic Checkpoints in Tumor-Infiltrating Primary Natural Killer Cells for CAR-NK Therapy With the rapid advancement of biotechnology and gene editing technologies, increasing attention is being paid to enhancing the clinical potential of natural killer (NK) cells in cancer therapy. Despite their potential in clin...